Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Pharmacogenetic Testing Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?#_x000D_
The pharmacogenetic testing market has experienced substantial expansion in recent years. Its valuation is projected to grow from $14.33 billion in 2025 to $16.58 billion in 2026, at a compound annual growth rate (CAGR) of 15.7%. The market’s historical growth can be attributed to advancements in genomic sequencing technologies, concerns regarding adverse drug reactions, the increasing burden of chronic diseases, declining genetic testing costs, and a rise in clinical awareness._x000D_
_x000D_
The pharmacogenetic testing market size is anticipated to undergo substantial growth over the next few years, with projections indicating it will reach $29.55 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 15.5%. This expansion during the forecast period is primarily driven by factors such as the advancement of precision healthcare, the broadening availability of direct-to-consumer testing, enhanced integration with electronic health records, increasing regulatory support, and greater investment in genomics research. Additionally, significant trends expected during this period include a rising adoption of personalized medicine, a more widespread use of genetic testing in drug selection, an expansion of its applications in oncology and cardiology, a growing demand for precision diagnostics, and the integration of pharmacogenomics into routine clinical practice._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Pharmacogenetic Testing Market Growth Drivers: What’s Behind The Acceleration?#_x000D_
The future growth of the pharmacogenetic testing market is anticipated to be boosted by the escalating need for personalized medicine. Personalized medicine, also known as precision medicine, is a healthcare strategy that customizes treatments and medical choices based on a person’s distinct genetic makeup, biological traits, and lifestyle. The heightened call for personalized medicine stems from its capacity to enhance treatment efficacy, facilitate early diagnosis, and improve cost efficiency in patient care. The pharmacogenetic testing market facilitates personalized medicine by examining an individual’s genetic profile to forecast drug reactions, thereby allowing for better treatment choices and minimizing the likelihood of negative side effects. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to 6 approvals in 2022. Consequently, the rising demand for personalized medicine is fueling the expansion of the pharmacogenetic testing market._x000D_
_x000D_
#Pharmacogenetic Testing Market Segment Landscape: Which Areas Lead Development?#_x000D_
The pharmacogenetic testing market covered in this report is segmented – _x000D_
_x000D_
1) By Type: Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, Single Gene Tests_x000D_
2) By Drug Type: Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, Over-The-Counter Medications_x000D_
3) By Therapeutic Area: Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology And Hypersensitivity, Dermatology, Gynecology, Oncology, Other Therapeutic Areas_x000D_
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, Direct-to-Customer Services_x000D_
5) By End User: Healthcare Providers, Pharmaceutical And Biotechnology Companies, Centers And Academic Institutes, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Whole Genome Sequencing: Illumina Sequencing, Ion Torrent Sequencing, Pacific Biosciences Sequencing, Oxford Nanopore Sequencing_x000D_
2) By Whole Exome Sequencing: Capture-Based Exome Sequencing, Targeted Enrichment Exome Sequencing, Hybridization-Based Exome Sequencing_x000D_
3) By Array-Based Tests: SNP Array Testing, Expression Array Testing, Copy Number Variation Array Testing_x000D_
4) By Single Gene Tests: Targeted Gene Panels, Mutation Detection Tests, Sequencing Of Specific Genes_x000D_
_x000D_
#Pharmacogenetic Testing Market Trends: What’s Defining The Industry’s Next Phase?#_x000D_
Key companies within the pharmacogenetics testing market are prioritizing the creation of advanced pharmacogenomics testing services, including prescription-based pharmacogenetic testing, to improve medication safety, enhance treatment precision, and support personalized therapeutic decision-making. Prescription-based pharmacogenetic testing involves genetic analyses initiated by licensed healthcare providers to investigate how an individual’s genetic composition influences their response to specific medications, thus empowering clinicians to optimize drug selection and dosing while mitigating the probability of adverse drug reactions. For instance, in May 2023, UCSF, a US-based healthcare organization, unveiled its pharmacogenomics testing service, which was designed to elevate the precision of medical treatments. This service equips healthcare professionals with genetic insights that aid in tailoring drug therapies to each patient’s unique profile, thereby strengthening drug efficacy and minimizing the risk of harmful side effects._x000D_
_x000D_
#Pharmacogenetic Testing Market Industry Leaders And Competitive Landscape#_x000D_
Major companies operating in the pharmacogenetic testing market are CVS Health Corporation, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Eurofins Scientific Inc., Bio-Rad Laboratories, Precision Medicine Advsiors, Azenta Life Sciences, Fulgent Genetics, Pacific Biosciences of California Inc., Castle Biosciences, 23andMe Holding Co., Helix Inc., Genomind Inc., MD Labs, Sonic Genetics, AutoGenomics Inc., LabClinics SA, Gene By Gene Ltd., Xcode Life Sciences, YouScript, RxGenomix LLC _x000D_
_x000D_
#View The Full Pharmacogenetic Testing Market Report:#_x000D_
_x000D_
#Pharmacogenetic Testing Market Geographic Analysis: Where Is Demand Rising Fastest?#_x000D_
Asia-Pacific was the largest region in the pharmacogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









